GL1X · GenesisL1 explorer

MolNFT v1 · #81881 · protein

Discovery of a selective trk inhibitor with efficacy in rodent cancer tumor models

3V5Q · Nt-3 growth factor receptor: “Discovery of a selective trk inhibitor with efficacy in rodent cancer tumor models”. X-ray diffraction, 2 ligands (0F4, CL), 3 pockets (best druggability 0.68). MolNFT v1 #81881 on GenesisL1: 3D…

PDB
3V5Q
Type
protein
Length
528 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Nt-3 growth factor receptor
EC
2.7.10.1
UniProt
Q16288
Ligands
0F4, CL
Pockets
3 · best druggability 0.68

Structure

x-ray diffraction · 2 distinct chains · 43% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANt-3 growth factor receptor (EC 2.7.10.1)protein26344% helix, 16% strandQ16288
BNt-3 growth factor receptor (EC 2.7.10.1)protein26543% helix, 17% strandQ16288

Ligands and binding sites

  • 0F4 · 1-(3-{[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-6-yl]amino}phenyl)-3-[3-(trifluoromethyl)phenyl]urea · ligand · 2 copies · chains A, B
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14290.680.79450F4
24620.670.79520F4
3520.360.7913empty

Interfaces

1 interface between chains.

  • A–B · 689 Ų buried · 6 hydrogen bonds · protein-protein

Compared structures

  • 3V5Q · Discovery of a selective TRK Inhibitor with efficacy in rodent cancer tumor models · the same entry in another collection · chain A against A, TM-score 1.00
  • Q16288 · AlphaFold monomer V2.0 prediction for nt-3 growth factor receptor (Q16288) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.